Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates

Impact · against what's priced in

TKNO's Q3 results show a positive trend in top-line growth and a narrowing net loss, beating revenue estimates. While the earnings beat is modest, the consistent pattern of surpassing revenue estimates over the last four quarters provides a positive signal for the company's growth trajectory.

TKNO+0.30

No priced-in read yet

In context

The company delivered a revenue beat of 8.58% ($12.7 million) and a 21.5% year-over-year increase in top-line growth, while narrowing its quarterly loss to $0.06 per share.

Read from the article alone

• earnings
• TKNO
• biomedical
• biopharma
• eps estimate
• genetics
• revenue beat

Search tags